ResMed Inc.
NYSE:RMDMedical - Devices
+$1.58 today
- Market cap
- $34.12B
- Beta
- 0.78
- P/E (TTM)
- 18.1
- EPS (TTM)
- $10.37
- Dividend yield
- 1.28%
Volume 1.22M
Average 1.32M
RMD Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
ResMed Inc.NYSE: RMD
Stock-Based Compensation · Q4 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q4 FY2026 stock-based compensation of $104.35M rose 321.6% year over year, ahead of the +97.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 289.5% from the prior quarter. Over 3 fiscal years it compounded at +13.6% a year.
Context
- Stock-based compensation amounted to 1.8% of revenue in FY2026, unchanged from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +321.6% holds above the trailing-twelve-month pace of +97.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2026
- 104.35M USD
- Year-over-year change
- +13.8%
- 4-year CAGR
- +12.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 104.35M | +13.8% |
| FY2025 | 2025-06-30 | 91.66M | +14.3% |
| FY2024 | 2024-06-30 | 80.18M | +12.7% |
| FY2023 | 2023-06-30 | 71.14M | +9.0% |
| FY2022 | 2022-06-30 | 65.26M | — |
Stock-Based Compensation vs competitors
How RMD compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +97.7% is the highest of 9, against a peer median of -1.3%.
- Stock-based compensation amounts to 3.2% of revenue for RMD, versus a peer median of 1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $835.3M USD | +9.6% | +15.4% | 7.2% | |
| LTM Jul 2026 | $496M USD | +14.8% | +8.8% | 1.3% | |
| LTM Jun 2026 | $181.24M USD | +97.7% | +13.6% | 3.2% | |
| LTM Jun 2026 | $166M USD | +5.7% | +10.8% | 0.8% | |
| LTM Jun 2026 | $119.43M USD | -8.2% | +35.8% | 13.3% | |
| LTM Jun 2026 | $118M USD | +6.3% | +24.7% | 0.6% | |
| LTM Jun 2026 | €112M EUR | -17.6% | — | 0.6% | |
| LTM Jun 2026 | $20.21M USD | -33.5% | — | 0.8% | |
| LTM Mar 2026 | $2.61M USD | -8.5% | +46.3% | 3.6% | |
| Peer median (excluding RMD) | — | -1.3% | +20.1% | 1.1% | |
Competitors are the stored peer set for RMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Net Income | 779.44M | 897.56M | 1.02B | 1.4B | 1.52B |
| Depreciation & Amortization | 193.84M | 197.56M | 216.21M | 235.81M | 244.15M |
| Deferred Income Tax | 0 | 216K | 0 | 0 | 0 |
| Stock-Based Compensation | 65.26M | 71.14M | 80.18M | 91.66M | 104.35M |
| Change in Working Capital | (708.08M) | (462.13M) | 44.78M | 16.74M | (74.24M) |
| Accounts Receivables | 19.35M | (106.51M) | (134.28M) | (76.68M) | (96.78M) |
| Inventory | (311.68M) | (248.83M) | 172.2M | (80.17M) | (9.92M) |
| Accounts Payables | (247.63M) | 31.34M | 0 | 90.96M | 172.72M |
| Other Working Capital | (168.11M) | (138.13M) | 6.86M | 82.63M | (140.26M) |
| Other Non-Cash Items | 20.69M | (11.05M) | 39.13M | 6.66M | 8.28M |
| Operating Cash Flow | 351.15M | 693.3M | 1.4B | 1.75B | 1.81B |
| Capital Expenditures | (156.04M) | (134M) | (114.86M) | (89.87M) | (156.29M) |
| Acquisitions (Net) | (42.78M) | (1.01B) | (133.46M) | (139.25M) | (350.72M) |
| Purchases of Investments | (20.72M) | (32.23M) | (22.46M) | (6.42M) | (28.54M) |
| Sales of Investments | 6.8M | 3.94M | 1M | 0 | 2.75M |
| Other Investing Activities | (17.18M) | 15.2M | (15.4M) | 35.48M | (12.41M) |
| Investing Cash Flow | (229.92M) | (1.16B) | (269.78M) | (200.05M) | (545.2M) |
| Debt Repayment | 122M | 665M | (730M) | (40M) | (10M) |
| Common Stock Issued | 47.38M | 49.14M | 53.09M | 74.44M | 74.5M |
| Common Stock Repurchased | 0 | 0 | (150.01M) | (300.03M) | (700.04M) |
| Dividends Paid | (245.34M) | (258.28M) | (282.32M) | (310.88M) | (349.66M) |
| Other Financing Activities | (52.41M) | (32.99M) | (10.05M) | (29.79M) | (21.83M) |
| Financing Cash Flow | (128.36M) | 422.87M | (1.12B) | (606.25M) | (1.01B) |
| Effect of Forex Changes | (14.43M) | (2.15M) | (1.72M) | 25.8M | 6.18M |
| Net Change in Cash | (21.57M) | (45.82M) | 10.47M | 971.09M | 259.78M |
| Free Cash Flow | 195.11M | 559.3M | 1.29B | 1.66B | 1.65B |
ResMed Inc.
NYSE:RMD
Intrinsic Alpha fair value
Locked
Current Price
$242.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.